AKR1B10 was reported to suppress tumor development and progression in colorectal cancer (33–37) and gastric cancer (55), but remains controversial in nasopharyngeal cancer (56, 57) and esophageal cancer (58, 59). Here, AKR1B10 is linked to nasopharyngeal carcinoma.